Inari Medical (NASDAQ:NARI) Price Target Raised to $80.00 at Piper Sandler

Inari Medical (NASDAQ:NARI) had its price target hoisted by Piper Sandler from $52.00 to $80.00 in a research note published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research analysts have also weighed in on the stock. Canaccord Genuity Group reissued a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Oppenheimer began coverage on Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price objective on the stock. Stifel Nicolaus initiated coverage on Inari Medical in a research report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Finally, Truist Financial upped their price target on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $68.00.

Inari Medical Trading Up 22.2 %

Inari Medical stock opened at $79.45 on Tuesday. Inari Medical has a 52 week low of $36.73 and a 52 week high of $79.50. The stock has a market cap of $4.65 billion, a P/E ratio of -58.85 and a beta of 0.97. The stock has a 50 day moving average of $52.85 and a 200-day moving average of $48.92.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction on Monday, December 16th. The stock was sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the sale, the director now owns 441,233 shares of the company’s stock, valued at $24,559,028.78. The trade was a 11.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,000 shares of company stock worth $10,527,870. 10.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Inari Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jennison Associates LLC grew its position in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock valued at $65,021,000 after buying an additional 610,468 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Inari Medical by 342.9% in the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after acquiring an additional 1,200,000 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after acquiring an additional 786,501 shares in the last quarter. Finally, Bamco Inc. NY increased its stake in shares of Inari Medical by 29.5% during the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock valued at $41,493,000 after acquiring an additional 228,977 shares during the period. 90.98% of the stock is currently owned by institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.